QuickView for Thy-1;jsessionid=011CF923678866240A0AFA39DB3FF7BC;jsessionid=469EB5DB5BA323E16AE04AF9D11394C5;jsessionid=8E43C2EF0A07BE06C199C1A34AF33D77;jsessionid=E349B3EF240C9E5D0C0BC0797D72157B;jsessionid=86CAE7C64FDBC95551D4A3E926BE013C;jsessionid=611141CF0D5404390E7335A2F4858DCA;jsessionid=DB635F77772D604586F862FD68D82329;jsessionid=B573C7F6AF2B39C9190381E357F6CDEB (gene)

1. CD7 activation regulates cytotoxicity-driven pathology in systemic sclerosis, yielding a target for …
2. An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leu…
3. Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
4. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblas…
5. Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplant…

There were no clinical trials for Thy-1;jsessionid=011CF923678866240A0AFA39DB3FF7BC;jsessionid=469EB5DB5BA323E16AE04AF9D11394C5;jsessionid=8E43C2EF0A07BE06C199C1A34AF33D77;jsessionid=E349B3EF240C9E5D0C0BC0797D72157B;jsessionid=86CAE7C64FDBC95551D4A3E926BE013C;jsessionid=611141CF0D5404390E7335A2F4858DCA;jsessionid=DB635F77772D604586F862FD68D82329;jsessionid=B573C7F6AF2B39C9190381E357F6CDEB